(Reuters) โ Bristol Myers Squibb said on Friday a trial evaluating a combination of its two cancer drugs failed to meet the primary goal to treat localized kidney cancer.
The combination of the two drugs โ Yervoy and top selling cancer drug Opdivo โ is already approved in the United States as a first line of treatment for patients with renal cell carcinoma that has spread.
However, the combination failed to meet the key endpoint of disease-free survival for patients who had localized form of the cancer and had undergone full or partial removal of the kidney.
Shares of Bristol Myers were down 1.1% premarket at $73.90.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
